Arcus Biosciences, Inc. (RCUS)
24.41
+0.58
(+2.43%)
USD |
NYSE |
Oct 09, 16:00
24.42
+0.01
(+0.04%)
Pre-Market: 20:00
Arcus Biosciences Enterprise Value : 2.512B for Oct. 9, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 09, 2026 | 2.512B |
| October 08, 2026 | 2.438B |
| October 07, 2026 | 2.526B |
| October 06, 2026 | 2.496B |
| October 05, 2026 | 2.554B |
| October 02, 2026 | 2.516B |
| October 01, 2026 | 2.616B |
| September 30, 2026 | 2.692B |
| September 29, 2026 | 2.670B |
| September 28, 2026 | 2.588B |
| September 25, 2026 | 2.583B |
| September 24, 2026 | 2.595B |
| September 23, 2026 | 2.764B |
| September 22, 2026 | 2.824B |
| September 21, 2026 | 2.708B |
| September 18, 2026 | 2.617B |
| September 17, 2026 | 2.656B |
| September 16, 2026 | 2.543B |
| September 15, 2026 | 2.501B |
| September 14, 2026 | 2.469B |
| September 11, 2026 | 2.535B |
| September 10, 2026 | 2.733B |
| September 09, 2026 | 3.030B |
| September 08, 2026 | 3.103B |
| September 04, 2026 | 3.179B |
| Date | Value |
|---|---|
| September 03, 2026 | 3.239B |
| September 02, 2026 | 3.203B |
| September 01, 2026 | 3.185B |
| August 31, 2026 | 3.131B |
| August 28, 2026 | 3.122B |
| August 27, 2026 | 3.297B |
| August 26, 2026 | 3.319B |
| August 25, 2026 | 3.421B |
| August 24, 2026 | 3.237B |
| August 21, 2026 | 3.265B |
| August 20, 2026 | 3.161B |
| August 19, 2026 | 3.266B |
| August 18, 2026 | 3.160B |
| August 17, 2026 | 3.166B |
| August 14, 2026 | 3.156B |
| August 13, 2026 | 3.077B |
| August 12, 2026 | 3.090B |
| August 11, 2026 | 3.062B |
| August 10, 2026 | 3.059B |
| August 07, 2026 | 3.047B |
| August 06, 2026 | 3.010B |
| August 05, 2026 | 2.930B |
| August 04, 2026 | 3.070B |
| August 03, 2026 | 2.920B |
| July 31, 2026 | 2.992B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Halozyme Therapeutics, Inc. | 14.51B |
| AVITA Medical, Inc. | 445.89M |
| Iovance Biotherapeutics, Inc. | 6.371B |
| Editas Medicine, Inc. | 304.84M |
| Recursion Pharmaceuticals, Inc. | 1.844B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -91.00M |
| Revenue (Quarterly) | 41.00M |
| Total Expenses (Quarterly) | 132.00M |
| EPS Diluted (Quarterly) | -0.7216 |
| Gross Profit Margin (Quarterly) | 95.12% |
| Profit Margin (Quarterly) | -222.0% |
| Earnings Yield | -16.00% |
| Normalized Earnings Yield | -16.00 |